Lynparza demonstrates survival benefit in early breast cancer, phase III trial data show

UC Davis Health and UCLA co-lead $16M study of AI use in breast cancer diagnosis

UC Davis Health and UCLA are co-leading a newly funded national clinical trial to evaluate whether AI can help radiologists interpret screening mammograms more accurately. The goal is to improve breast cancer detection and reduce unnecessary callbacks and anxiety for patients.

September 26, 2025

Vol.51 No.35

Clinical Roundup

Tecvayli + Darzalex Faspro achieves 100% MRD negativity in newly diagnosed MM, phase II study shows

An investigational immune-based induction regimen with Tecvayli (teclistamab-cqyv) and Darzalex Faspro (daratumumab and hyaluronidase-fihj) demonstrated meaningful clinical efficacy in transplant-eligible patients with newly diagnosed multiple myeloma.

September 26, 2025

Vol.51 No.35

Clinical Roundup

Mammograms may benefit women well into their 80s, UCLA study finds

For many older women, the question of whether to continue breast cancer screening has been uncertain. While most guidelines recommend mammograms up to age 74, advice for women 75 and older has been less clear.

September 26, 2025

Vol.51 No.35

In Brief

City of Hope expands clinical trial access across U.S. with new national model

City of Hope launched a national clinical trials model to expand access to emerging life-saving cancer treatments to more patients across the country.

September 19, 2025

Vol.51 No.34

Clinical Roundup

Libtayo + chemo shows significant improvement in OS for advanced NSCLC, phase III EMPOWER-Lung 3 trial shows

Libtayo (cemiplimab) plus chemotherapy demonstrates a more than double five-year overall survival rate of 19.4%, compared to 8.8% with chemotherapy alone, according to late-breaking data from exploratory analyses at World Conference on Lung Cancer.

September 19, 2025

Vol.51 No.34

Clinical Roundup

Rezatapopt monotherapy shows confirmed responses of eight solid tumor types in PYNNACLE phase II clinical trial

Rezatapopt monotherapy generated a 33% overall response rate in 97 patients with solid tumors spanning across eight different cancers (ovarian, lung, breast, endometrial, head and neck, colorectal, gallbladder, and ampullary carcinoma) and a median duration of response of 6.2 months, according to PYNNACLE phase II clinical trial interim data. These were patients whose tumors were TP53 Y220C mutated and KRAS wild-type.

September 19, 2025

Vol.51 No.34

Lynparza demonstrates survival benefit in early breast cancer, phase III trial data show

YOU MAY BE INTERESTED IN

UC Davis Health and UCLA co-lead $16M study of AI use in breast cancer diagnosis

Tecvayli + Darzalex Faspro achieves 100% MRD negativity in newly diagnosed MM, phase II study shows

Mammograms may benefit women well into their 80s, UCLA study finds

City of Hope expands clinical trial access across U.S. with new national model

Libtayo + chemo shows significant improvement in OS for advanced NSCLC, phase III EMPOWER-Lung 3 trial shows

Rezatapopt monotherapy shows confirmed responses of eight solid tumor types in PYNNACLE phase II clinical trial

Renew today!

Subscriber content

Never miss an issue!

Login